9
DISCUSSIONS IN ANTERIOR SEGMENT DISEASE ALAN G. KABAT, OD, FAAO MEMPHIS, TN [email protected] JOSEPH SOWKA, OD, FAAO ANDREW GURWOOD, OD, FAAO FT. LAUDERDALE, FL PHILADELPHIA, PA [email protected] [email protected] Course Description: Case presentations provide a springboard for in- depth discussion of several challenging anterior segment conditions. Emphasis is placed on understanding the presentation, pathophysiology and management of the various clinical entities. Learning Objectives/Outcomes: At the conclusion of this course, the attendee will be able to: 1. Identify the pathophysiology, clinical presentation and management of bacterial keratitis; 2. Identify the pathophysiology, clinical presentation and management of dacryoadenitis; 3. Identify the pathophysiology, clinical presentation and management of corneal laceration; 4. Identify the pathophysiology, clinical presentation and management of uveitis, as well as the essential laboratory work up; 5. Identify the pathophysiology, clinical presentation and management of herpes simplex keratitis; 6. Identify the pathophysiology, clinical presentation and management of recurrent corneal erosion. BACTERIAL KERATITIS Breakdown of corneal defenses (dry eyes, corneal trauma, corneal hypoxia, etc.)

Discussions in Anterior Segment Disease

  • Upload
    adi-tri

  • View
    216

  • Download
    0

Embed Size (px)

DESCRIPTION

anterior segment eye

Citation preview

discussions in anterior segment disease

ALAN G. KABAT, OD, FAAOMEMPHIS, [email protected]

JOSEPH SOWKA, OD, FAAO ANDREW GURWOOD, OD, FAAOFT. LAUDERDALE, FL PHILADELPHIA, [email protected] [email protected]

Course Description: Case presentations provide a springboard for in-depth discussion of several challenging anterior segment conditions. Emphasis is placed on understanding the presentation, pathophysiology and management of the various clinical entities.Learning Objectives/Outcomes: At the conclusion of this course, the attendee will be able to:1. Identify the pathophysiology, clinical presentation and management of bacterial keratitis; 2. Identify the pathophysiology, clinical presentation and management of dacryoadenitis; 3. Identify the pathophysiology, clinical presentation and management of corneal laceration; 4. Identify the pathophysiology, clinical presentation and management of uveitis, as well as the essential laboratory work up; 5. Identify the pathophysiology, clinical presentation and management of herpes simplex keratitis; 6. Identify the pathophysiology, clinical presentation and management of recurrent corneal erosion.

BACTERIAL KERATITIS Breakdown of corneal defenses (dry eyes, corneal trauma, corneal hypoxia, etc.) Introduction of pathogen (corneal abrasion mismanagement, contact lenses, etc.) Proliferation of organisms and release of toxins and proteolytic enzymes Antigen-antibody reaction Stromal edema (splitting of stromal collagen lamellae sheets) Cellular transudation and emigration Infiltration Phagocytosis of organisms with proteolytic enzyme release and stromal lysis Antigenic neutralization (hopefully) Cicatrization (fibroblastic proliferation of scar tissue) Visual loss

Clinical Picture of Bacterial Keratitis Pain, photophobia, lacrimation Profound conjunctival and episcleral injection Involvement of innocent bystanding tissue Anterior chamber reaction Possible (sterile) hypopyon Focal infiltrate with overlying epithelial staining and breakdown The spectrum of clinical findings is broad (from an initially mild, often misdiagnosed presentation of S. aureus to the exaggerated presentation of Pseudomonas) Any staining infiltrate should be presumed to be an infectious ulcer until proven otherwise

Management of Bacterial Keratitis Cultures and sensitivity studies Broad spectrum antibiosis: Fluoroquinolones1. Ciprofloxacin (Ciloxan) ii gtt Q15min X 6hrs, then ii gtt Q 30min X 18 hrs. 2. Ocuflox Q30 minutes while awake, and then BID at night is as effective as fortified antibiotics.3. Levofloxacin (Quixin)?4. New alternatives- fourth generation fluoroquinolones: Vigamox/ Moxeza (moxafloxacin); Zymar/ Zymaxid (gatifloxacin) Q1H Equal gram (-) coverage, greater gram (+) coverage than earlier generation fluoroquinolones5. Newest options: Besivance (besifloxacin), Moxeza (moxifloxacin), Zymaxid (gatifloxacin) Cycloplegics (scopolamine 0.25% TID or atropine 1% BID) - decreases blood-aqueous barrier breakdown Corticosteroids (reduces inflammation by constricting blood vessel walls and reducing vessel wall permeability. Also blocks prostaglandin formation and release and stabilizes lysosomal membranes). Use corticosteroids only if step 1 is successfully completed (clinical impressions vs. microbiologic study results).

DACRYOADENITIS Inflammation of the lacrimal gland Usually seen in younger adults May be acute or chronic: Acute form presents with greater pain, redness & symptomology; usually infectious in nature (bacterial or viral) Chronic form is more common; usually inflammatory & due to underlying systemic autoimmune disease (e.g. sarcoidosis, Sjgren's syndrome, systemic lupus erythematosus, Wegener's granulomatosus)

Acute Dacryoadenitis - Typically unilateral Ocular redness, tearing, & swelling of the upper lid Painful proptosis & ophthalmoparesis May have associated preauricular lymphadenopathy & fever Chronic Dacryoadenitis - Usually bilateral S-shaped swelling to outer of the eyelid Pain is variable Swollen lacrimal gland is often evident on lid retraction

Dacryoadenitis: Diagnostic management Orbital CT or MRI Laboratory studies CBC with differential Serology based on history & associated symptoms (e.g. ACE, FTA-ABS, RPR, PPD with anergy panel) Transcutaneous, transeptal biopsy should be performed in recalcitrant cases of dacryoadenitis or when a malignant process is suspected

Dacryoadenitis: Therapeutic Management Acute - warrants systemic antibiotics Amoxicillin (250-500 mg po q8h) Cephalexin (250-500 mg po q6h) In more severe cases, hospitalization with IV antibiotics may be necessary Chronic dacryoadenitis may be managed with a course of systemic steroids Typical therapy involves 80-100 mg of oral prednisone daily for 1-2 weeks, followed by slow taper. PENETRATING INJURY: CORNEAL LACERATION Excessive PAIN, decreased vision Deeper than abrasion; may be smaller, linear + Seidels sign; additionally, may see hyphema, A/C rxn, flattened A/C (relative), air bubbles in A/C Iris prolapse possible IOP is low -- DO NOT perform tonometry! Management Photodocument (if possible for clinicolegal purposes) MINIMAL manipulation of the globe! Avoid topical medications! Shield the eye but DO NOT PATCH! N.P.O. Refer IMMEDIATELY for surgical repair

ANTERIOR UVEITIS Associated factors An inflammation of the iris and ciliary body May result from direct trauma to the eye (most often) May occur as a result of inflammation of other ocular structures (e.g., keratitis, scleritis) May be associated with underlying systemic disease (including but not limited to): ankylosing spondylitis Behets disease inflammatory bowel disease juvenile rheumatoid arthritis Reiters syndrome sarcoidosis syphilis tuberculosis Lyme disease Improper management may result in secondary, inflammatory glaucoma Signs and Symptoms Signs: Variable redness Ptosis or blepharospasm (due to discomfort) Tearing Visual acuity normal to mildly reduced 20/40 or better in most cases More difficulty with near / accommodative tasks

Symptoms: Deep, dull achy pain in affected eye and orbit Extreme photophobia Hazy vision Biomicroscopic evaluation Mild lid congestion (pseudoptosis); palpebral conjunctiva is unaffected Circumlimbal flush , i.e., injection of the episclera and conjunctiva concentrated around the cornea Mild corneal edema Keratic precipitates in chronic conditions (granulomatous) Anterior chamber cells & flare ** cells = white blood cells liberated from uveal blood vessels flare = proteinaceous by-products of inflammation Posterior or (less commonly) anterior synechia Iris nodules Altered intraocular pressure Initially reduced because of secretory hypotony Inflammatory by-products clog the trabecular meshwork, inducing IOP elevation May range from 30 to 80 mmHg in extreme cases

Management 2 primary goals:1. immobilize the iris & ciliary body to decrease pain and prevent exacerbation2. quell the inflammatory response to prevent ocular sequelae STRONG topical cycloplegics Choice of drug dependent upon severity of reaction, iris color, and presumed patient compliance Best choices include % scopolamine 1% atropine Topical corticosteroids Must be deeply penetrating and efficacious Must be given FREQUENTLY, particularly during early stages of treatment Drug choices include: difluprednate ** prednisolone acetate loteprednol ? Address synechiae using 1% atropine + 10% phenylephrine topically Elevated IOP should be addressed using standard topical antiglaucoma therapy: -blockers (e.g., Timoptic, Betoptic) CAIs (e.g., Trusopt) Prostaglandin analogs (e.g., Xalatan) offer no clinical benefit Miotics (e.g., pilocarpine) are ABSOLUTELY CONTRAINDICATED

In recurrent cases (i.e., two or more similar presentations), a thorough medical evaluation to ascertain underlying etiology is indicated CXR Sacroiliac joint films Serology: CBC with differential ESR ANA HLA-B27 RF ACE FTA-ABS Lyme titer

Herpes Simplex Keratitis Pathophysiology: Initial infection by herpes simplex virus occurs in childhood (hand to eye, mouth to eye) After initial infection, virus enters a dormant phase in cell ganglia "Trigger factors" induce reactivation of viral replication throughout the patient's life; include: fever, emotional stress, exposure to UV radiation, menstruation, trauma, immunosuppression About half of all infected patients experience re-activation within 5 years Most commonly ocular manifestion is dendritic epithelial keratitis More severe presentations can manifest as geographic epithelial keratitis

Clinical presentation - dendritic keratitis: Branching epithelial ulcer; may begin as nondescript punctate epitheliopathy Stains centrally with NaFl, peripherally with rose bengal or lissamine green ("terminal end-bulbs") Associated conjunctival injection, edema; uveitis possible Recurrent attacks lead to corneal hypoesthesia, i.e. diminished corneal sensitivity (+) Cotton-wisp test Patients may be far less symptomatic than predicted by ocular appearance

Management: Herpes virus cannot be eradicated; management efforts are aimed at suppression and amelioration of symptoms Historical tandard of care in U.S. is topical trifluridine 1% q2h - 9 times daily, tapered to q3-4h as ulcer shows signs of closure; maintain at QID for at least 7-10 days. More recent option is ganciclovir 0.15% ophthalmic gel 5 times daily until resolution, then reduced to TID for 7 days Oral acyclovir may be used in patients who lack dexterity or compliance with topicals (400 mg po five times daily) Corticosteroids are absolutely contraindicated in active epithelial infection Herpetic Eye Disease Study (HEDS) 1998: Acyclovir 400 mg po BID X 12 months may reduce rate of recurrence by as much as 50%

RECURRENT CORNEAL EROSION History, History, History History of Corneal Abrasion Previous episodes of RCE Pain on awakening A breakdown of the epithelial layer of the cornea due to a breach in the integrity of the basement membrane Common Etiologies: Corneal dystrophy (e.g. granular dystrophy) Trauma; often follows improperly treated corneal abrasion Can present as a small epithelial defect or as a large abrasion Treatment Bandage SCL Pressure patching in rare instances Prophylactic ntibiotic Cycloplegic Artificial Tears and Hypertonic agents Anterior Stromal Puncture (ASP) Oral doxycycline + topical steroids Amniotic membrane ?